Search

We dig into the story of Lonza in China, and its new HPAPI expansion in Guangzhou

This Scottish company is developing a thin film that could improve medicine adherence in the elderly

Viral vectors can enable innovative medical treatments, but only with a comprehensive formulation development plan

Ukrainian drug discovery has been disrupted by war. We spoke to leaders of its largest player about the domestic industry’s past, present, and future.

The war in Ukraine has massively impacted clinical trials. We spoke to one man tracking the disruption.

From improving solubility and bioavailability to making formulations suitable for inhalation – micronization is a versatile technique.

Viral vector manufacture has come a long way, but the story is far from over.

The Medicine Maker is proud to present the Power List 2022 and the inaugural Company of the Year Awards

Clinical trials suffer from heavy dropout rates. Perhaps the answer is a little care and attention.

PCI has focused on becoming a trusted CDMO partner by building strong working relationships with clients.